tiprankstipranks
Trending News
More News >
Alnylam Pharmaceuticals (ALNY)
:ALNY
Advertisement

Alnylam Pharma (ALNY) AI Stock Analysis

Compare
1,282 Followers

Top Page

ALNY

Alnylam Pharma

(NASDAQ:ALNY)

Rating:52Neutral
Price Target:
$422.00
▲(0.74% Upside)
Alnylam Pharma's overall score is driven by strong earnings call results and positive corporate events, reflecting growth potential and strategic initiatives. However, ongoing financial performance challenges and valuation concerns weigh down the score. Technical indicators show strong momentum but caution for potential pullback due to overbought conditions.
Positive Factors
Financial Performance
ALNY reported $492mm in Amvuttra sales, which was well above consensus expectations, elevating buyside expectations.
Market Expansion
ALNY received regulatory approval in Brazil, Europe, the UK, and Japan for its therapies, expanding its market reach.
Sales Growth
Alnylam Pharmaceuticals raised its full-year product revenue guidance, indicating strong sales performance and growth potential.
Negative Factors
Profit Margins
A 30% royalty payment to Sanofi affects Alnylam's margins, making Amvuttra less profitable.
Stock Valuation
Lofty stock valuation is a concern, as it is significantly higher than typical for a profitable biotech.
Valuation Concerns
Alnylam's valuation is stretched, which still raises concerns despite positive market performance.

Alnylam Pharma (ALNY) vs. SPDR S&P 500 ETF (SPY)

Alnylam Pharma Business Overview & Revenue Model

Company DescriptionAlnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
How the Company Makes MoneyAlnylam Pharmaceuticals generates revenue primarily through the sale of its RNAi-based therapeutic products. The company earns money from product sales, particularly from its commercialized medicines such as ONPATTRO, GIVLAARI, and OXLUMO, which target specific genetic disorders. In addition to product sales, Alnylam also engages in strategic collaborations and partnerships with other pharmaceutical companies, which provide additional revenue streams through milestone payments, licensing fees, and royalties. These partnerships often involve the joint development and commercialization of RNAi therapeutics, leveraging Alnylam's technology platform and expertise in RNA interference.

Alnylam Pharma Key Performance Indicators (KPIs)

Any
Any
Revenue by Segment
Revenue by Segment
Analyzes income from different business areas, highlighting which segments drive growth and profitability, and indicating strategic focus areas.
Chart InsightsAlnylam Pharma's revenue growth is largely driven by the impressive performance of AMVUTTRA, which has shown strong uptake and favorable patient access, particularly in the U.S. TTR franchise. Despite a decline in Onpattro sales, the company's strategic focus on TTR leadership and innovation is yielding results, with a 28% year-over-year revenue increase. The earnings call highlights a positive outlook, with expectations of achieving sustainable profitability by the end of 2025, supported by successful product launches and ongoing pipeline advancements.
Data provided by:Main Street Data

Alnylam Pharma Earnings Call Summary

Earnings Call Date:Jul 31, 2025
(Q2-2025)
|
% Change Since: 23.28%|
Next Earnings Date:Oct 23, 2025
Earnings Call Sentiment Positive
Alnylam's Q2 2025 earnings call highlights strong revenue growth driven by successful product launches and increased guidance, despite some decreased collaboration revenue and increased operating expenses. The overall sentiment is positive due to the significant achievements and strong financial performance.
Q2-2025 Updates
Positive Updates
Record-Breaking TTR Franchise Revenue
TTR franchise revenues reached $544 million, marking a 77% year-over-year growth, largely driven by the AMVUTTRA CM launch.
Strong Overall Financial Performance
Alnylam reported its strongest quarter to date with $672 million in total net product revenues, representing a 64% growth year-over-year.
Increased Revenue Guidance for 2025
Total net product revenues guidance for 2025 increased from $2.05 billion-$2.25 billion to a revised range of $2.65 billion-$2.8 billion, a 27% increase at the midpoint.
Successful AMVUTTRA Launch
Approximately 1,400 cardiomyopathy patients were receiving AMVUTTRA by June 30, contributing an estimated $150 million in revenue.
FDA Fast Track Designation for Nucresiran
Nucresiran received Fast Track Designation from the FDA for ATTR-CM, promising a more streamlined review process.
International Expansion
Launched AMVUTTRA in Germany and Japan, with further global expansion underway in Europe, Japan, and Brazil.
Negative Updates
Decreased Collaboration Revenue
Collaboration revenue fell by $166 million compared to last year, primarily due to the modification of the cemdisiran collaboration agreement with Regeneron.
Decreased Gross Margin on Product Sales
Gross margin on product sales was 79%, down from 84% in the second quarter of 2024, due to increased royalties on AMVUTTRA.
Increased Operating Expenses
Non-GAAP R&D expenses increased 11% and SG&A expenses increased 26% compared to last year, driven by increased headcount and investments in AMVUTTRA's launch.
Company Guidance
During the Alnylam Q2 2025 earnings call, the company provided robust guidance based on strong performance metrics. Alnylam reported total net product revenues of $672 million, marking a 64% increase year-over-year, driven by 77% growth in the TTR franchise, primarily due to the AMVUTTRA ATTR-CM launch. The company observed a 51% increase in global TTR product revenues compared to Q1 2025, with approximately 1,400 cardiomyopathy patients receiving AMVUTTRA, contributing about $150 million in revenue. As a result, Alnylam increased its 2025 total net product revenue guidance from $2.05-$2.25 billion to $2.65-$2.8 billion, representing a $575 million increase or 27% at the midpoint. The updated guidance assumes significant contributions from international markets in the second half of the year and reflects expectations for sustained growth across the portfolio, underscored by the successful early uptake of AMVUTTRA in both first-line and stabilizer-progressor patient populations.

Alnylam Pharma Financial Statement Overview

Summary
Alnylam Pharma shows promising revenue growth but struggles with profitability and operational efficiency. The balance sheet reveals high leverage, posing financial risk, yet strong liquidity from cash reserves provides some stability. Cash flow challenges persist, despite positive financing activities. The company's trajectory suggests potential, but risks tied to profitability and leverage need to be addressed for sustainable growth.
Income Statement
62
Positive
The income statement reveals a mixed performance for Alnylam Pharma. Despite a substantial revenue growth from $1.03 billion in 2022 to $2.35 billion TTM, the company continues to operate at a net loss, with a net profit margin of -11.49% TTM. Gross profit margin remains strong at 89.04% TTM, indicating efficient cost management. However, negative EBIT and EBITDA margins of -4.91% and -6.22% respectively, highlight ongoing operational challenges. While revenue growth is promising, the lack of profitability is a concern.
Balance Sheet
55
Neutral
Alnylam Pharma's balance sheet shows a high level of debt relative to equity, with a debt-to-equity ratio of 11.27 TTM, indicating significant leverage. The return on equity (ROE) remains negative due to ongoing losses. However, the equity ratio is 2.74% TTM, which is positive but still reflects a weak equity position. The company's high level of cash and short-term investments is a positive aspect, providing liquidity support.
Cash Flow
58
Neutral
The cash flow statement highlights some positive trends, with a significant financing cash flow of $309.33 million TTM, bolstering liquidity. However, both operating cash flow and free cash flow remain negative, indicating ongoing cash burn from operations and capital expenditures. The operating cash flow to net income ratio is negative, further emphasizing cash flow challenges despite a minor improvement in free cash flow growth.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue2.46B2.25B1.83B1.04B844.29M492.85M
Gross Profit2.06B1.92B1.52B868.60M704.14M414.80M
EBITDA-170.93M-178.85M-258.24M-926.56M-661.56M-736.33M
Net Income-319.09M-278.16M-440.24M-1.13B-852.82M-858.28M
Balance Sheet
Total Assets4.57B4.24B3.83B3.55B3.64B3.41B
Cash, Cash Equivalents and Short-Term Investments2.86B2.69B2.44B2.19B2.44B1.87B
Total Debt1.30B1.30B1.31B1.32B997.59M521.19M
Total Liabilities4.32B4.17B4.05B3.70B3.06B2.39B
Stockholders Equity250.59M67.09M-220.64M-158.22M588.20M1.02B
Cash Flow
Free Cash Flow-52.09M-42.59M41.95M-613.33M-718.07M-685.32M
Operating Cash Flow-15.54M-8.31M104.16M-541.27M-641.69M-614.96M
Investing Cash Flow-110.77M-116.84M-336.35M169.35M-273.30M-435.52M
Financing Cash Flow231.59M294.16M172.13M425.75M1.25B994.98M

Alnylam Pharma Technical Analysis

Technical Analysis Sentiment
Positive
Last Price418.91
Price Trends
50DMA
322.12
Positive
100DMA
290.12
Positive
200DMA
274.07
Positive
Market Momentum
MACD
22.89
Negative
RSI
86.25
Negative
STOCH
96.18
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALNY, the sentiment is Positive. The current price of 418.91 is above the 20-day moving average (MA) of 340.46, above the 50-day MA of 322.12, and above the 200-day MA of 274.07, indicating a bullish trend. The MACD of 22.89 indicates Negative momentum. The RSI at 86.25 is Negative, neither overbought nor oversold. The STOCH value of 96.18 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ALNY.

Alnylam Pharma Risk Analysis

Alnylam Pharma disclosed 45 risk factors in its most recent earnings report. Alnylam Pharma reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Alnylam Pharma Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
$13.79B11.8119.30%17.62%19.89%
76
Outperform
$21.32B15.4612.78%2.27%1.15%37.75%
74
Outperform
$42.74B31.6224.75%89.58%
58
Neutral
$26.70B-1.81%0.58%-764.64%
53
Neutral
$21.63B-123.93%-99.70%
52
Neutral
$54.91B-257.82%5.01%-330.09%
51
Neutral
$7.39B0.40-62.86%2.37%15.56%-1.99%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ALNY
Alnylam Pharma
418.91
148.45
54.89%
UTHR
United Therapeutics
304.81
-26.23
-7.92%
SMMT
Summit Therapeutics
29.13
18.89
184.47%
ARGX
Argenx Se
674.90
149.65
28.49%
BNTX
BioNTech SE
110.03
29.50
36.63%
RPRX
Royalty Pharma
37.91
12.51
49.25%

Alnylam Pharma Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
Alnylam Pharma Appoints New Chief R&D Officer
Positive
Jun 18, 2025

On June 12, 2025, Alnylam Pharmaceuticals announced the integration of its Research and Early Development function with its Development function into a single organization, appointing Pushkal Garg as Executive Vice President, Chief Research and Development Officer. This strategic move aims to accelerate pipeline progress and foster collaboration, enhancing Alnylam’s ability to deliver RNAi therapeutics to all major tissues by 2030, thus potentially transforming patient care across a range of diseases.

The most recent analyst rating on (ALNY) stock is a Buy with a $328.00 price target. To see the full list of analyst forecasts on Alnylam Pharma stock, see the ALNY Stock Forecast page.

Executive/Board ChangesShareholder Meetings
Alnylam Pharma Re-elects Directors at Annual Meeting
Neutral
May 13, 2025

On March 10, 2025, Alnylam Pharma held its Annual Meeting where stockholders re-elected four Class III directors to serve until 2028. Additionally, stockholders approved several key proposals, including a Certificate of Amendment, the Second Amended and Restated 2018 Stock Incentive Plan, and the compensation of named executive officers. PricewaterhouseCoopers LLP was ratified as the independent auditor for the fiscal year ending December 31, 2025.

The most recent analyst rating on (ALNY) stock is a Buy with a $328.00 price target. To see the full list of analyst forecasts on Alnylam Pharma stock, see the ALNY Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 01, 2025